Gewählte Publikation:
SHR
Neuro
Krebs
Kardio
Lipid
Stoffw
Microb
Richtig, G; Cerroni, L; Schmidt, H; Beham-Schmid, C; Deinlein, T; Vallant, C; Richtig, E.
Talimogene laherparepvec can initiate plasma cell invasion into infiltrated melanoma lesions - a case series.
J Eur Acad Dermatol Venereol. 2021; 35(3):e209-e211
Doi: 10.1111/jdv.16922
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
-
Richtig Georg
- Co-Autor*innen der Med Uni Graz
-
Beham-Schmid Christine
-
Cerroni Lorenzo
-
Kränke Teresa Maria
-
Richtig Erika
-
Schmidt Helmut
-
Vallant Christina Martha
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
-
Talimogene laherparepvec (T-VEC) is a genetically engineered herpes simplex virus type 1 (HSV-1) and used in locally advanced melanoma patients. Its mode of action is not fully understood. We present three cases where T-VEC caused monoclonal as well as polyclonal B-cell infiltration.
This article is protected by copyright. All rights reserved.